Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
Othman T, Baird JH, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE.
Othman T, et al. Among authors: phillips t.
Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19521. Online ahead of print.
Br J Haematol. 2024.
PMID: 38797530
No abstract available.